CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-22 | Borgeson Blake Director | Sale | −8,885 | $8.91 | $79K | 7,460,730 |
| 2023-08-16 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 888,186 |
| 2023-08-16 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $8.90 | $223K | 863,186 |
| 2023-08-16 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,410,135 | ||
| 2023-08-15 | Larson Tina Marriott President and COO | Shares withheld for taxes 10b5-1 | −5,378 | $9.18 | $49K | 418,782 |
| 2023-08-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −16,913 | $9.19 | $155K | 873,806 |
| 2023-08-15 | Virani Shafique Chief Business Officer | Shares withheld for taxes 10b5-1 | −3,603 | $9.19 | $33K | 140,351 |
| 2023-08-15 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +18,000 | $2.22 | $40K | 158,351 |
| 2023-08-15 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −18,000 | $9.25 | $167K | 140,351 |
| 2023-08-15 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −18,000 | 451,469 | ||
| 2023-08-15 | Secora Michael Chief Financial Officer | Shares withheld for taxes 10b5-1 | −4,727 | $9.19 | $43K | 838,186 |
| 2023-08-15 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 875,686 |
| 2023-08-15 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $9.27 | $232K | 850,686 |
| 2023-08-15 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,485,135 | ||
| 2023-08-09 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 900,719 | ||
| 2023-08-09 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 890,719 | ||
| 2023-08-09 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,521,496 | ||
| 2023-08-08 | Borgeson Blake Director | Sale | −14,498 | $11.03 | $160K | 7,472,887 |
| 2023-08-08 | Borgeson Blake Director | Sale | −3,272 | $11.75 | $38K | 7,469,615 |
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +8,674 | $11.40 | $99K | 924,484 |
Page 33 of 41 · 805 trades